blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3789397

EP3789397 - NOVEL SPECIFIC-BINDING POLYPEPTIDES AND USES THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  03.11.2023
Database last updated on 13.09.2024
FormerGrant of patent is intended
Status updated on  15.06.2023
FormerExamination is in progress
Status updated on  21.01.2022
FormerRequest for examination was made
Status updated on  17.09.2021
FormerThe application has been published
Status updated on  05.02.2021
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): IT, PL, PT, SK		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Pieris Pharmaceuticals GmbH
Zeppelinstrasse 3
85399 Hallbergmoos / DE
[2021/10]
Inventor(s)01 / HINNER, Marlon
Eugen Papststrasse 9
81247 Munich / DE
02 / WIEDENMANN, Alexander
Silcherweg 4
89542 Herbrechtingen / DE
03 / ALLERSDORFER, Andrea
Mozartstrasse 20A
85283 Wolnzach / DE
 [2021/10]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2021/10]
Application number, filing date20185401.520.05.2015
[2021/10]
Priority number, dateEP2014016948822.05.2014         Original published format: EP 14169488
[2021/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3789397
Date:10.03.2021
Language:EN
[2021/10]
Type: B1 Patent specification 
No.:EP3789397
Date:06.12.2023
Language:EN
[2023/49]
Search report(s)(Supplementary) European search report - dispatched on:EP03.02.2021
ClassificationIPC:C07K14/00, C07K19/00, A61K38/16, C07K14/54, C07K14/47
[2021/10]
CPC:
C07K14/47 (EP,CN,KR,RU,US); A61K38/00 (EP,CN,RU,US); A61P29/00 (EP,RU);
A61P37/06 (EP); A61P43/00 (EP); C07K14/54 (KR);
C12P21/02 (RU); G01N33/6869 (CN,RU,US); G01N33/6893 (KR);
C07K2319/31 (KR); G01N2333/47 (CN); G01N2333/525 (KR);
G01N2333/54 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/42]
Former [2021/10]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGE POLYPEPTIDE MIT SPEZIFISCHER BINDUNG UND VERWENDUNGEN DAVON[2021/10]
English:NOVEL SPECIFIC-BINDING POLYPEPTIDES AND USES THEREOF[2021/10]
French:NOUVEAUX POLYPEPTIDES DE LIAISON SPÉCIFIQUE ET LEURS UTILISATIONS[2021/10]
Examination procedure06.09.2021Amendment by applicant (claims and/or description)
09.09.2021Examination requested  [2021/42]
09.09.2021Date on which the examining division has become responsible
20.01.2022Despatch of a communication from the examining division (Time limit: M04)
27.05.2022Reply to a communication from the examining division
16.06.2023Communication of intention to grant the patent
24.10.2023Receipt of the translation of the claim(s)
26.10.2023Fee for grant paid
26.10.2023Fee for publishing/printing paid
Parent application(s)   TooltipEP15727573.6  / EP3145945
Fees paidRenewal fee
10.08.2020Renewal fee patent year 03
10.08.2020Renewal fee patent year 04
10.08.2020Renewal fee patent year 05
10.08.2020Renewal fee patent year 06
18.05.2021Renewal fee patent year 07
25.05.2022Renewal fee patent year 08
26.05.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.12.2023
CZ06.12.2023
EE06.12.2023
ES06.12.2023
HR06.12.2023
IT06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
PL06.12.2023
RO06.12.2023
RS06.12.2023
SE06.12.2023
SK06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
PT08.04.2024
[2024/36]
Former [2024/35]AT06.12.2023
CZ06.12.2023
EE06.12.2023
ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RO06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/34]EE06.12.2023
ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/33]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/32]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/26]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
Former [2024/21]LT06.12.2023
BG06.03.2024
GR07.03.2024
Former [2024/20]GR07.03.2024
Documents cited:Search[I]WO2007149032  (ASTRAZENECA AB [SE], et al) [I] 1-15 * pages 1,36; claims 51-53 * * pages 58,60; claims 57-59 *;
 [A]WO2012156219  (ABLYNX NV [BE], et al) [A] 1-15* pages 80-81, *;
 [I]  - CHEN YI ET AL, "Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis", THE JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, (20060501), vol. 116, no. 5, doi:10.1172/JCI25308, ISSN 0021-9738, pages 1317 - 1326, XP002583205 [I] 1-15 * page 1317 - page 1326 *

DOI:   http://dx.doi.org/10.1172/jci25308
 [I]  - KIKLY K ET AL, "The IL-23/Th"1"7 axis: therapeutic targets for autoimmune inflammation", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 18, no. 6, ISSN 0952-7915, (20061201), pages 670 - 675, (20061201), XP027932748 [I] 1-15 * page 670 - page 675 *
 [I]  - WEISS G A ET AL, "ANTICALINS VERSUS ANTIBODIES: MADE-TO-ORDER BINDING PROTEINS FOR SMALL MOLECULES", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, (20000801), vol. 7, no. 8, doi:10.1016/S1074-5521(00)00016-8, ISSN 1074-5521, pages R177 - R184, XP001079019 [I] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/S1074-5521(00)00016-8
 [I]  - SKERRA A, "'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties", REVIEWS IN MOLECULAR BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, (20010601), vol. 74, no. 4, doi:10.1016/S1389-0352(01)00020-4, ISSN 1389-0352, pages 257 - 275, XP002269554 [I] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/S1389-0352(01)00020-4
 [A]  - SCHLEHUBER S ET AL, "Anticalins as an alternative to antibody technology", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (20050101), vol. 5, no. 11, doi:10.1517/14712598.5.11.1453, ISSN 1471-2598, pages 1453 - 1462, XP009101205 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1517/14712598.5.11.1453
 [A]  - HOHLBAUM A M ET AL, "Anticalins(R): The lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies", EXPERT REVIEW OF CLINICAL IMMUNOLOGY, FUTURE DRUGS LTD., LONDON, GB, (20070101), vol. 3, no. 4, doi:10.1586/1744666X.3.4.491, ISSN 1744-666X, pages 491 - 501, XP001538450 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1586/1744666X.3.4.491
 [A]  - SKERRA ARNE, "Anticalins as alternative binding proteins for therapeutic use", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, (20070801), vol. 9, no. 4, ISSN 1464-8431, pages 336 - 344, XP009101213 [A] 1-15 * abstract *
 [A]  - ARNE SKERRA, "Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities", FEBS JOURNAL, (20080624), vol. 275, no. 11, doi:10.1111/j.1742-4658.2008.06439.x, ISSN 1742-464X, pages 2677 - 2683, XP055099855 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1111/j.1742-4658.2008.06439.x
by applicantWO9916873
 WO9964016
 WO0075308
 US6177074
 US6403564
 US6500930
 WO03029463
 WO03029471
 US2003069395
 US6620413
 US6696245
 WO2005019256
 WO2006056464
 WO2007038619
 US7250297
 WO2012004384
    - ROUVIER et al., J. Immunol, (19930000), vol. 150, pages 5445 - 5556
    - YAO et al., Immunity, (19950000), vol. 3, pages 811 - 821
    - YAO et al., J. Immunol, (19950000), vol. 755, no. 12, pages 5483 - 5486
    - FOSSIEZ et al., J. Exp. Med., (19960000), vol. 183, no. 6, pages 2593 - 2603
    - SPRIGGS et al., J. Clin. Immunol, (19970000), vol. 17, pages 366 - 369
    - KOLLS et al., Immunity, (20040000), vol. 21, pages 467 - 476
    - KAWAGUCHI et al., J. Allergy Clin. Immunol, (20040000), vol. 114, no. 6, pages 1267 - 1273
    - MOSELEY et al., Cytokine Growth Factor Rev., (20030000), vol. 14, no. 2, pages 155 - 174
    - LUBBERTS E., Cytokine, (20080000), vol. 41, pages 84 - 91
    - ANTONYSAMY et al., J. Immunol, (19990000), vol. 162, pages 577 - 584
    - VAN KOOTEN et al., J. Am. Soc. Nephrol., (19980000), vol. 9, pages 1526 - 1534
    - MOLET et al., J. Allergy Clin. Immunol., (20010000), vol. 108, pages 430 - 438
    - TEUNISSEN et al., J. Invest. Dermatol, (19980000), vol. 111, pages 645 - 649
    - KURASAWA et al., Arthritis Rheum., (20000000), vol. 43, pages 2455 - 2463
    - B. OPPMANN et al., Immunity, (20000000), vol. 13, page 715
    - M. T. WIEKOWSKI et al., J Immunol, (20010000), vol. 166, page 7563
    - D.M. FRUCHT, Sci STKE, (20020108), vol. 2002, no. 114, page PE1
    - ALTSCHUL, S. F. et al., Nucl. Acids Res., (19970000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - SMITH et al., J. Mol. Biol., (19810000), vol. 147, pages 195 - 197
    - FLOWER, D.R. et al., Biochim. Biophys. Acta, (20000000), vol. 1482, pages 337 - 350
    - MALLAT, Z. et al., Circulation, (20010000), vol. 104, pages 1598 - 603
    - HELLINGS, P. W. et al., Am. J. Resp. Cell Mol. Biol., (20030000), vol. 28, pages 42 - 50
    - MATUSEVICIUS, D. et al., Multiple Sclerosis, (19990000), vol. 5, pages 101 - 104
    - ZIOLKOVVSKA, M. et al., J. Immunol., (20000000), vol. 164, pages 2832 - 38
    - KOTAKE, S. et al., J. Clin. Invest., (19990000), vol. 103, pages 1345 - 52
    - KOMIYAMA, Y. et al., J. Immunol., (20060000), vol. 177, pages 566 - 573
    - JOVANOVIC et al., J. Immunol, (19980000), vol. 161, pages 3513 - 3521
    - TEUNISSEN et al., J. Investig. Dermatol, (19980000), vol. 111, pages 645 - 649
    - SHALOM- BARAK et al., J. Biol Chem., (19980000), vol. 273, pages 27467 - 27473
    - ATTUR et al., Arthritis Rheum., (19970000), vol. 40, pages 1050 - 1053
    - AGGARWAL et al., J. Leukoc. Biol, (20020000), vol. 71, no. 1, pages 1 - 8
    - LUBBERTS et al., "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion", Arthritis Rheum., (20040000), vol. 50, pages 650 - 659, XP002580291
    - BIASUCCI, L. et al., Circulation, (19990000), vol. 99, pages 855 - 860
    - BLANKENBERG, S. et al., Circulation, (20020000), vol. 106, pages 2595 - 30
    - BUFFON, A. et al., NEJM, (20020000), vol. 347, pages 55 - 7
    - MALLAT, Z. et al., Circ Res., (20010000), vol. 89, pages E41 - 5
    - HOLSCHER, Curr. Opin. Invest. Drugs, (20050000), vol. 6, page 489
    - LANGRISH et al., Immunol Rev., (20040000), vol. 202, page 96
    - J. Biol. Chem., (20030000), vol. 278, pages 1910 - 191
    - J. Exp. Med., (20050000), vol. 201, pages 233 - 240
    - STARNES et al., "Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production", J. Immunol., (20010000), vol. 167, pages 4137 - 4140, XP001206023
    - PARK et al., Immunol, (20050000), vol. 6, page 1133
    - CHEN et al., J Clin Invest., (20060000), vol. 116, page 1317
    - KONIG, T.SKERRA, A., J. Immunol. Methods, (19980000), vol. 218, pages 73 - 83
    - SCHLEHUBER, S.SKERRA, A., "Duocalins, engineered ligand-binding proteins with dual specificity derived from the lipocalin fold", Biol. Chem., (20010000), vol. 382, doi:10.1515/BC.2001.166, pages 1335 - 1342, XP001078830

DOI:   http://dx.doi.org/10.1515/BC.2001.166
    - PERVAIZ, S.BREW, K., FASEB J., (19870000), vol. 1, pages 209 - 214
    - FLOWER, D.R., Biochem. J., (19960000), vol. 318, pages 1 - 14
    - SCHMIDT, T.G.M. et al., J. Mol. Biol., (19960000), vol. 255, pages 753 - 766
    - VAJODUCKWORTH, Pharmacol. Rev., (20000000), vol. 52, pages 1 - 9
    - DENNIS, M. S.ZHANG, M.MENG, Y. G.KADKHODAYAN, M.KIRCHHOFER, D.COMBS, D.DAMICO, L. A., J Biol Chem, (20020000), vol. 277, pages 35035 - 35043
    - OSBORN, B.L. et al., J. Pharmacol. Exp. Ther., (20020000), vol. 303, pages 540 - 548
    - FUERTGES et al., "The Clinical Efficacy of Poly(Ethylene Glycol)-Modified Proteins J", Control. Release, (19900000), vol. 11, doi:10.1016/0168-3659(90)90127-F, pages 139 - 148, XP023744014

DOI:   http://dx.doi.org/10.1016/0168-3659(90)90127-F
    - LOWMAN, H.B., Annu. Rev. Biophys. Biomol. Struct., (19970000), vol. 26, pages 401 - 424
    - RODI, D.J.MAKOWSKI, L., Curr. Opin. Biotechnol., (19990000), vol. 10, pages 87 - 93
    - VENTURI et al., J. Mol. Biol., (20020000), vol. 315, pages 1 - 8
    - BRUCKDORFER, T. et al., Curr. Pharm. Biotechnol., (20040000), vol. 5, pages 29 - 43
    - III. et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions", Protein Eng, (19970000), vol. 10, pages 949 - 57
    - MARTIN et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6", EMBO J, (19940000), vol. 13, pages 5303 - 9, XP002076260
    - HOLLIGER et al., "Diabodies': small bivalent and bispecific antibody fragments", PNAS USA, (19930000), vol. 90, doi:10.1073/pnas.90.14.6444, pages 6444 - 6448, XP002008022

DOI:   http://dx.doi.org/10.1073/pnas.90.14.6444
    - TRAUNECKER et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells", EMBO J, (19910000), vol. 10, pages 3655 - 3659, XP000232579
    - TRAUNECKER et al., "Janusin: new molecular design for bispecific reagents", Int J Cancer, (19920000), pages 51 - 52, XP009171574
    - SILVERMAN, LU QBAKKER ATO WDUGUAY AALBA BMSMITH RRIVAS ALI PLE HWHITEHORN E, Nat Biotech, (20051200), vol. 23, no. 12, pages 1556 - 61
    - SILVERMAN JLU QBAKKER ATO WDUGUAY AALBA BMSMITH RRIVAS ALI PLE H, Nat Biotech, vol. 23, no. 12, pages 1556 - 61
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.